3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Adult Solid Neoplasm
1
Interventions
Carboplatin
15
durvalumab
14
Etoposide
14
pembrolizumab
9
atezolizumab
9
Cisplatin
9
Topotecan
8
Nivolumab
7
Specimen Handling
6
olaparib
4
berzosertib
4
Temozolomide
4
Magnetic Resonance Spectroscopy
4
AMG 757
4
tremelimumab
3
Radiotherapy
3
Radiosurgery
3
PM 01183
3
Ipilimumab
3
Docetaxel
3
Biopsy
3
niraparib
2
lenvatinib
2
cabozantinib
2
Platinum
2
Irinotecan
2
Fulvestrant
2
veliparib
1
tislelizumab
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Small Cell Lung Carcinoma
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled